In this article, Charles River Associates (CRA) delves into why traditional vaccine procurement schemes are not fit for purpose during the pandemic and how both governments and manufacturers must adapt to manage the greater level of risk associated with pandemic vaccine development and distribution.
As the COVID-19 pandemic continues around the world, global efforts among industry stakeholders to develop, manufacture and secure the supply of proven effective vaccines have soldiered on. There are currently more than 80 vaccine candidates in clinical development (more than 15 of which are in Phase 3 trials) and more than 180 candidates in pre-clinical development, according to the World Health Organization (WHO).1 And with several front runners including Pfizer-BioNTech, Moderna, AstraZeneca and Johnson & Johnson (J&J) already delivering vaccines, the months ahead are looking brighter.
But there are challenges that procurement bodies such as governments and supranational organisations face as COVID-19 vaccines are approved on an emergency or conditional basis. On one hand, procurement bodies need to ensure that they secure ample supply of available vaccines and that eligible populations can access them as soon as possible to protect both people and healthcare systems – and to invigorate economies. On the other hand, there is uncertainty around whether these vaccines can prevent transmission and whether they will be effective against emerging and future COVID-19 variants. There are ongoing investigations regarding the effectiveness of current vaccines against new variants.
Unique considerations for vaccines during a pandemic
When procuring or buying vaccines, traditional tender-based approaches often rely on buyers’ ability to weigh several available options and make informed decisions. While vaccine procurement has evolved over recent years, such approaches are not workable or feasible during a pandemic when there is a race to rapidly develop and produce vaccines. Manufacturers have had to scale up production before they, and other stakeholders including procurement bodies, know whether their vaccine will achieve regulatory approval.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
Despite efforts by manufacturers to scale up production capacity, demand for vaccines has outstripped supply. This presents a challenge for governments and other organisations responsible for acquiring vaccines, as they must compete with other procurement bodies on a global scale to secure enough of the limited supply.
During the H1N1 pandemic in 2009, some countries entered into advanced purchase agreements very quickly and secured most of the available supply, whereas countries that were behind the curve in deal making faced being left without access to vaccine supply. In the case of the H1N1 pandemic, it was milder than stakeholders initially anticipated and the demand for immunisation was low,2 leading countries that had entered advanced agreements to try to cancel their orders, donate their supply or dispose of unused vaccines.
Despite efforts by manufacturers to scale up production capacity, demand for vaccines has outstripped supply
The COVID-19 pandemic has been a different story so far. Many countries and supranational organisations began efforts to secure supply early in the pandemic by either investing in vaccine developers/manufacturers or striking advance purchase agreements:
Some procurement bodies have been slower to enter into agreements, as seen with the EU’s Joint Procurement Agreement (JPA) – a mechanism that was initially established in 2009 when member states were unable to access vaccines during the H1N1 pandemic. Although the European Commission’s vaccine strategy document states that it aims to transfer some of the risks from industry to public authorities in order to assure member states have equitable and affordable access to an available vaccine, members of the JPA have been slow in entering into purchasing agreements with manufacturers. Some EU member states have signed separate agreements with certain vaccine manufacturers.
Government bodies in Canada, the US and UK have signed agreements with multiple manufacturers and secured large volumes of vaccines.3 Despite limited clinical data for many of these vaccine candidates at the time of signing these contracts, by entering into several different agreements these countries have been able to spread their risk and, even with a few failures, have likely secured an adequate supply of vaccine for their populations.
Nonetheless, we have seen countries struggle with vaccine supplies due to production problems and policy barriers with trade. In addition, some countries are facing organisational and distribution issues in their pandemic immunisation programmes. We are also witnessing the emergence of newer COVID-19 variants and the aforementioned uncertainty around the effectiveness of currently approved vaccines on these variants.
Different approaches for managing risk and budget
To address the challenges that both procurement bodies and manufacturers face during a pandemic, governments must accept that they need to assume more risk than in a typical vaccine procurement scenario due to the urgent need. If not, they risk delaying vaccine availability for their citizens and potentially putting people’s health at risk.
Conversely, manufacturers must recognise the challenges that procurement bodies face and be realistic about their funding expectations and system affordability. Both parties may need to explore more innovative risk-sharing agreements to satisfy their interests. We have explored two risk‑share constructs that can help manufacturers and procurement bodies to balance risks that they face in a pandemic situation.
1. Multi-year contract with staggered payments over time
In this approach, procurement bodies contract with manufacturers for multiple years and only need to pay a proportion of the total order value upfront. The rest of the order value would be paid in a staggered manner over a period of time.
Benefits for procurement bodies: Structuring payments this way helps mitigate the high up‑front cost that would otherwise be associated with intensive pandemic immunisation programmes. The procurement bodies only need to pay a portion of the total order volume upfront and as a result they can enter into agreements with multiple manufacturers who have potential vaccines in development. This will be especially helpful for procurement bodies of countries with less-than-adequate budgets for securing vaccine supplies.
Benefits for vaccine manufacturers: The vaccine manufacturers will receive a portion of the order value upfront, which will help them to expand production capacity and secure raw materials. Additionally, with longer contracts, manufacturers would be assured of the ability to supply for multiple years – potentially also during the post-pandemic phase.
2. Performance-based contracts
In this approach, the eventual payment to manufacturers would be linked to the performance of their vaccine. Contracting parties could define performance using metrics such as ability to stop transmission or ability to adapt for future variants. The COVID-19 vaccines currently being supplied are approved on an emergency/conditional basis. The data available for these vaccines are limited and there is uncertainty around whether they would stop the spread of the virus in addition to prevention of disease. Additionally, it is unclear how effective these vaccines would be against emerging new strains of the virus. In the past, we have seen the performance-based approach implemented for pneumococcal vaccine in Finland, as well as in other therapeutic areas such as procurement of antibiotics.
Benefits for procurement bodies: Procurement bodies could be confident that they would not be paying full price for vaccines that lack efficacy against transmission or possible future variants.
Benefits for manufacturers: Manufacturers would be able to realise rewards in line with the value of their product, meaning more adaptable vaccines would be better rewarded. This approach may benefit manufacturers using a more adaptable platform, such as mRNA technology.
Innovative vaccine procurement contracts that offer a more agreeable distribution of risk and budget impact could also yield other benefits for stakeholders:
Manufacturers would potentially have more flexibility when determining the price of their vaccine – they could price it more affordably in the early phase of the pandemic, while securing further commitments in the post-pandemic era.
By willingly entering into innovative agreements with procurement bodies, it shows industry stakeholders that a manufacturer recognises the investments the public has made in their company and the importance of equitable access to a vaccine. Although some investments came with ties, we have seen vaccine manufacturers facing negative media coverage after a Belgian politician accidently revealed EU COVID-19 vaccine prices.
These types of agreements also provide a platform for sharing risk over time, for several months or even years. Manufacturers and governments can develop co-responsibility for managing risks associated with the limited safety and efficacy data of a vaccine.
Innovative vaccine procurement approaches could also act as longer-term solutions beyond just the initial rounds of pandemic procurement and could be adapted for future pandemic situations. This may result in a broader set of procurement bodies and manufacturers collaborating and engaging in discussions earlier in a pandemic to ensure predictability for all parties and faster access to vaccines in the post‑pandemic phase.
Abhishek Kumar
Abhishek5 is an Associate Principal at CRA where he manages strategic projects in the area of pricing and market access, commercial strategy and portfolio strategy.
Kees Chamberlain
Kees5 is a Consulting Associate at CRA who has been supporting clients in developing strategies for COVID-19 vaccines.
Eva Marchese, PhD
Eva5 is a Vice President at CRA who specialises in competitive strategy, pricing, market access and research primarily in the pharmaceutical, biotech and life sciences industries.
Anthony Barron
Anthony5 is a Principal in the Life Sciences Practice at CRA based in Brussels. He has been working on European and international pharmaceuticals policy issues for more than 10 years.
References
Draft landscape and tracker of COVID-19 candidate vaccines [Internet]. Who.int. 2021 [cited 30 March 2021]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
Raude J, Caille-Brillet A, Setbon M. The 2009 pandemic H1N1 influenza vaccination in France: who accepted to receive the vaccine and why?. PLoS Currents. 2010;2:RRN1188.
Coronavirus: AstraZeneca to begin making potential vaccine [Internet]. BBC News. 2021 [cited 30 March 2021]. Available from: https://www.bbc.co.uk/news/business-52917118
Charles River Associates [Internet]. Crai.com. 2021 [cited 30 March 2021]. Available from: https://www.crai.com
The views expressed in this article are the authors’ and not those of Charles River Associates (CRA)4 or any of the organisations with which the authors are affiliated.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.
This article was very useful to my study. Thank you.